Incivek
(telaprevir)ApprovedSmall molecule
Vertex PharmaceuticalsTelaprevir is used to treat hepatitis C, a viral infection that affects the liver. It works by stopping the hepatitis C virus from reproducing in the body.[2] Incivek is currently approved and in use across 5 indications[4].[1]
Incivek is one of 172 small molecule programs targeting HIV infection. It is currently in Approved.
5
Indications
63
Total Trials
0
Active Trials
171
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
123 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Incivek
Vertex PharmaceuticalsApproved
Arava
SanofiApproved
Mycobutin
PfizerApproved
Cabenuva
GSKApproved
Golytely
BayerApproved
Hepsera
GileadApproved
Zofran
NovartisApproved
Viread
GileadApproved
Lotrimin
BayerApproved
Zometa
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatitis C14 trials
Show 11 more trials
Chronic Hepatitis10 trials
Show 7 more trials
Interaction6 trials
Chronic Hepatitis C Virus Infection4 trials
Show 1 more trial
Efficacy and Safety3 trials
18 more indications
Hepatitis C Virus Infection3 trials
Liver Transplant3 trials
Combination Therapy2 trials
TED2 trials
Hepatic Impairment2 trials
Trial2 trials
ESS1 trial
HIV-11 trial
Tacrolimus1 trial
Adult Subject1 trial
HIV1 trial
Renal Impairment1 trial
Interleukin1 trial
Hepatocellular Carcinoma1 trial
Effectiveness1 trial
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
Completed·—·N/A·NCT02113631·50 enrolled
Regulatory
FDA Approval Timeline[5]
May 23, 2011
INCIVEK
NDA NDA201917
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Incivek drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for telaprevir. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Hepatitis C Virus Serine Protease, NS3/NS4A Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
May 30, 2028
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8431615May 30, 2028